Seizures Among Children Treated with Whole-Plant Cannabis Fall 86%


2021-12-16 02:00:12 Ganjapreneur


The frequency of epileptic seizures among 10 children treated with whole-plant cannabis medicine fell by an average of 86%, according to research published in the journal BMJ Paediatrics Open outlined by SciTechDaily. None of the children in the study had responded to any other conventional treatments. Just two of the children who participated in the study responded to Epidyolex, the only purified CBD product children with seizure conditions are allowed access to under England’s National Health Service (NHS). The children who participated in the study ranged from ages one to 13, with an average age of six, and had a range of epileptic conditions, including infantile spasms, learning disabilities, and global developmental delays, the report says. The children had tried an average of seven conventional epilepsy drugs, which fell to an average of one each after starting the medical cannabis regimen — seven of the children stopped taking conventional drugs completely. On average, the children took an average of 5.15 milligrams of THC and 171.8 milligrams of CBD daily, although the researchers are still conducting a full chemical analysis of the whole-plant products. Parents and caregivers reported significant improvements in their child’s sleep, appetite, behavior, and cognition after they started to take whole-plant cannabis medicine, and only a few minor side effects, such as fatigue, were reported. “Further research is required to elucidate the mechanisms by which the respective additive constituents of whole-plant products lead to superior clinical results,” the researchers wrote. “We believe that our data on whole-plant medical cannabis in childhood-onset severe treatment-resistant epilepsy, provide evidence to support its introduction into the NHS within current NICE prescribing guidelines,” the researchers concluded. “Such a move would be hugely beneficial to the families, who in addition to having the psychological distress of looking after their chronically ill children, have also to cover the crippling financial burden of their medication.” The average monthly cost of medicinal cannabis products was 874 British pounds ($1,158). One child that participated in the study had obtained their prescription for free on the NHS. Get daily news insights in your inbox. Subscribe End Authored By: TG joined Ganjapreneur in 2014 as a news writer and began hosting the Ganjapreneur podcast in 2016. He is based in upstate New York, where he also teaches media studies at a local university.
根据Scitechdaily概述的发表在《BMJ儿科开放》杂志上的研究,10名接受全植物大麻药物治疗的儿童癫痫发作的频率平均下降了86%。研究中的儿童没有一个对任何其他传统治疗有反应。 参与这项研究的儿童中只有两名对Epidyolex有反应,这是英国国民健康服务体系(NHS)允许患有癫痫的儿童使用的唯一纯化的CBD产品。报告称,参与这项研究的儿童年龄从1岁到13岁不等,平均年龄为6岁,患有一系列癫痫疾病,包括婴儿痉挛、学习障碍和全球发育迟缓。 这些儿童平均尝试了7种传统的癫痫药物,在开始医用大麻方案后,这一比例下降到平均每人一种--其中7名儿童完全停止服用传统药物。平均而言,这些儿童平均每天摄入5.15毫克四氢大麻酚和171.8毫克CBD,尽管研究人员仍在对全植物产品进行全面的化学分析。 父母和照顾者报告说,在他们开始服用全植物大麻药物后,他们的孩子的睡眠、食欲、行为和认知有了显著改善,只报告了一些轻微的副作用,如疲劳。 研究人员写道:“需要进一步的研究来阐明全植物产品各自的添加剂成分导致卓越临床结果的机制。” 研究人员总结说:“我们认为,我们关于全植物医用大麻在儿童期严重耐治疗癫痫中的数据提供了证据,支持在目前的NICE处方指南中将其引入国民保健制度。”“这样的举措将对这些家庭大有裨益,他们除了有照顾慢性病孩子的心理痛苦之外,还必须支付他们药物治疗的严重经济负担。” 药用大麻产品的平均每月成本为874英镑(1158美元)。参与这项研究的一名儿童在国民健康保险制度上免费获得了他们的处方。 在收件箱中获取每日新闻见解。订阅 结束 作者: TG于2014年加入Ganjapreneur担任新闻作家,并于2016年开始主持Ganjapreneur播客。他住在纽约州北部,在当地的一所大学教授媒体研究。